Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 14/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560584 | 0.91 | PTGER1 (0.72) | PTGER1NPSR1LMNAGAACYP1A2 | |
| SCHEMBL561193 | 0.88 | PTGER1 (0.56) | PTGER1NPSR1LMNAGAACYP1A2 | |
| SCHEMBL561142 | 0.88 | PTGER1 (0.56) | PTGER1NPSR1LMNAGAACYP1A2 | |
| SCHEMBL561589 | 0.86 | PTGER1 (0.54) | PTGER1NPSR1LMNAGAACYP1A2 | |
| SCHEMBL562199 | 0.85 | PTGER1 (0.59) | PTGER1NPSR1LMNAGAACYP1A2 | |
| SCHEMBL561320 | 0.85 | PTGER1 (0.55) | PTGER1NPSR1LMNAGAACYP1A2 | |
| SCHEMBL562105 | 0.85 | PTGER1 (0.59) | PTGER1NPSR1LMNAGAACYP1A2 | |
| SCHEMBL560938 | 0.84 | PTGER1 (0.55) | PTGER1NPSR1LMNAGAACYP1A2 | |
| SCHEMBL562072 | 0.84 | PTGER1 (0.56) | PTGER1 | |
| SCHEMBL7875050 | 0.84 | PTGER1 (0.62) | PTGER1NPSR1LMNAGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2010122088-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | RYR2, PAICS, CTRC | PTGER1 1951/4885NPSR1 3980/4885LMNA 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.